Elonva (corifollitropin alfa) / Organon - LARVOL DELTA

Feasibility and efficacy of random-start progestin-primed ovarian stimulation: a multicenter pilot randomized controlled trial in oocyte donation. (PubMed, Reprod Biol Endocrinol) - No abstract available

Journal

Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol (clinicaltrials.gov) - P=N/A | N=252 | Not yet recruiting | Sponsor: ART Fertility Clinics LLC | Initiation date: Jul 2025 ➔ Dec 2025

Trial initiation date

TROPIX: Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA) (clinicaltrials.gov) - P=N/A | N=318 | Recruiting | Sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA | Not yet recruiting ➔ Recruiting

Enrollment open • Infertility • Sexual Disorders

A single dose of corifollitropin alfa is equipotent to a daily dose of 300 IU recombinant FSH regardless of ovarian reserve. (PubMed, Reprod Biomed Online) - "Regardless of ovarian reserve, a single dose of CFA provides a similar ovarian response as daily 300 IU recFSH in patients undergoing IVF/intracytoplasmic sperm injection."

Journal

Etonogestrel implant for LH suppression in a novel DuoStim ovarian stimulation protocol using overlapping doses of corifollitropin alfa for social egg freezing: a case report. (PubMed, JBRA Assist Reprod) - "Our report is the first to highlight that a woman attempting fertility preservation while using an ENG implant for contraception may benefit from LH suppression during COS. Additionally, it proposes a novel protocol that applies CFA in overlapping doses, aiming for comfort and lower cost."

Journal • Women's Health

Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol (clinicaltrials.gov) - P=N/A | N=252 | Not yet recruiting | Sponsor: ART Fertility Clinics LLC | Initiation date: Apr 2025 ➔ Jul 2025

Trial initiation date

Continuous Double Ovarian Stimulation. (clinicaltrials.gov) - P4 | N=30 | Completed | Sponsor: Instituto Bernabeu | Recruiting ➔ Completed

Trial completion

The efficacy of intraovarian versus subcutaneous corifollitropin alfa administration in DuoStim protocol for infertile women with low in vitro fertilization response. (PubMed, J Obstet Gynaecol Res) - "The study revealed that intraovarian injection of corifollitropin alfa may enhance the quality of oocytes retrieved, particularly Grade B oocytes, in women with poor response to IVF under the DuoStim protocol, while both methods exhibited similar outcomes in terms of demographic factors, cycle duration, and gonadotropin dosage."

Clinical • Journal • Preclinical • Gynecology • Infertility • Sexual Disorders

A novel long-acting recombinant follicle-stimulating hormone with hyperglycosylation exhibits improved pharmacokinetic and bioactivity on promoting follicle growth. (PubMed, Biochem Pharmacol) - "Although Recombinant human FSH (rh-FSH) and long-acting FSH analogs, such as FSH-CTP (Elonva), have been used to treat infertility for many years...Furthermore, increased activities in terms of ovary weight gain and superovulations were verified in rats. In conclusion, the designed hyperglycosylated FSH164 exhibits a prolonged metabolic duration, with a single dose of FSH164 possessing bioactivity comparable to that of multiple rh-FSH injections, suggesting that it has great potential as a therapy for infertility."

Journal • PK/PD data • Infertility • Sexual Disorders

Randomized controlled trial to evaluate the impact of follicle priming on IVM outcomes in women with polycystic ovaries: CFA versus FSH-B. (PubMed, Hum Reprod) - P3 | "While follicle priming for IVM using one injection of CFA in subfertile patients with high AFC results in a trend towards lower oocyte retrieval rates compared to daily injections of FSH-B, the use of CFA in IVM cycles is safe, convenient, and as efficacious as priming with FSH-B."

Journal • Polycystic Ovary Syndrome

Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol with Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol (clinicaltrials.gov) - P=N/A | N=252 | Not yet recruiting | Sponsor: ART Fertility Clinics LLC

New trial

One-shot Ovarian Stimulation Protocol (One-shot) (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Fundación Santiago Dexeus Font | Trial completion date: Jan 2025 ➔ Apr 2025 | Trial primary completion date: Jan 2025 ➔ Apr 2025

Trial completion date • Trial primary completion date • Infertility • Sexual Disorders

Development of a Long-Acting Follicle-Stimulating Hormone Using Serum Albumin Fab-Associated Technology for Female Infertility. (PubMed, Endocrinol Metab (Seoul)) - "Even corifollitropin alfa, with an extended half-life, requires supplementary injections of rhFSH after 7 days...These findings suggest that SAFA-FSH presents a promising alternative to current rhFSH treatments for female infertility. However, further research is essential to thoroughly assess its safety and efficacy in clinical contexts."

Journal • Gynecology • Infertility • Sexual Disorders

One-shot Ovarian Stimulation Protocol (One-shot) (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Fundación Santiago Dexeus Font | Not yet recruiting ➔ Recruiting

Enrollment open • Infertility • Sexual Disorders

One-shot Ovarian Stimulation Protocol (One-shot) (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: Fundación Santiago Dexeus Font

New trial • Infertility • Sexual Disorders

Therapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Fertil Steril) - "Specific interventions such as testosterone seem to correlate with a better live birth rate in women with diminished ovarian reserve; these findings should be further explored in randomized trials."

Journal • Retrospective data • Review

Reproductive outcome after in vitro fertilization in endometriosis - key factors and implications. (PubMed, J Med Life) - "Our study revealed that treatment with corifollitropin alfa in the endometriosis group was associated with a higher clinical pregnancy rate. AMH and age proved to be significant independent factors for the reproductive outcome."

Journal • Preclinical • Retrospective data • Endometriosis • Gynecology • Infertility • Inflammation • Pain • Sexual Disorders • Women's Health

Pretreatment with luteal estradiol for programming antagonist cycles compared to no pretreatment in advanced age women stimulated with corifollitropin alfa: a non-inferiority randomized controlled trial. (PubMed, Hum Reprod) - P3 | "Programming antagonist cycles with luteal E2 pretreatment seems a useful tool in advanced age women to better schedule oocyte retrievals on working days. However, the potential benefit of the number of collected oocytes remains to be demonstrated in a larger population displaying the characteristics of decreased ovarian reserve encountered in Poseïdon classification."

Head-to-Head • Journal • Metastases • Gynecology

Vaginal micronized progesterone on preventing luteinizing hormone untimely surge in ART cycles: A prospective proof-of-concept study. (PubMed, JBRA Assist Reprod) - "Progestin-Primed Ovarian Stimulation with micronized vaginal progesterone seems to be a compelling choice for preventing premature ovulation without compromising oocyte quality in women undergoing ovarian stimulation."

Journal

PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study (clinicaltrials.gov) - P4 | N=60 | Not yet recruiting | Sponsor: University Hospital, Ghent | Initiation date: Apr 2024 ➔ Jul 2024

Trial initiation date

Single-chain human follicle-stimulating hormone with a di-N-glycosylated linker. (PubMed, Theriogenology) - "Our data show that sc-hFSH L0N and sc-hFSH LNN produced from both cell lines stimulate cAMP and progesterone production in mLTC cells expressing hFSH receptors and exhibit similar B/I (in vitro Bioactivity/Immuno activity) ratios. Finally, the ratio of in vivo/in vitro bioactivities for sc-hFSH LNN relative to natural pituitary heterodimeric hFSH increased 8-fold, most likely because of a longer half-life in the blood."

Journal

PE-PMA: Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial (clinicaltrials.gov) - P4 | N=110 | Completed | Sponsor: IRCCS San Raffaele | Active, not recruiting ➔ Completed

Trial completion • Infertility • Sexual Disorders

PE-PMA: Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial (clinicaltrials.gov) - P4 | N=110 | Active, not recruiting | Sponsor: IRCCS San Raffaele | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Feb 2023 ➔ Apr 2024 | Trial primary completion date: Aug 2022 ➔ Feb 2024

Enrollment closed • Trial completion date • Trial primary completion date • Infertility • Sexual Disorders

PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study (clinicaltrials.gov) - P4 | N=60 | Not yet recruiting | Sponsor: University Hospital, Ghent | Initiation date: Jan 2024 ➔ Apr 2024

Trial initiation date

TROPIX: Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA) (clinicaltrials.gov) - P=N/A | N=318 | Not yet recruiting | Sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA

New trial • Infertility • Sexual Disorders